Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 9 August 2023 AM
There's a shake-up looming for the sector's Top 10 companies by cardiovascular drug sales, with earnings forecast to fall across all but one pharma over the next five years.
According to analysis by Evaluate Pharma, current leader Novartis, is expected to hold onto its crown, despite global heart drug sales falling from US$7.8 billion in 2023 to US$6.9 billion in 2028.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.